Biogen Celebrates 30th Anniversary With $2 Billion Investment In New Manufacturing Facility At North Carolina’s Research Triangle Park

Biogen Inc. has announced plans to invest an additional $2 billion in expanding its manufacturing facilities in North Carolina’s Research Triangle Park (RTP), a site that has been central to the company’s operations since 1995. This new investment will build on Biogen’s long-standing presence in the region, where it has already invested around $10 billion in its manufacturing infrastructure, including over $3 billion in recent years. The upcoming expansion aims to support the advancement of Biogen’s late-stage clinical pipeline and further strengthen its ability to deliver innovative treatments to patients worldwide.

Over the next few years, Biogen will focus on expanding its capabilities across its two RTP campuses. Planned investments include enhancing its antisense oligonucleotide (ASO) manufacturing infrastructure, building out clinical and commercial fill-finish platforms that can support multiple types of therapies, and upgrading production technologies with advanced automation and artificial intelligence tools. These initiatives reflect Biogen’s commitment to staying at the forefront of manufacturing innovation while ensuring flexibility and scalability across its product portfolio.

Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, stated, “We are proud of our longstanding commitment to manufacturing innovation, investment, and collaboration with the Research Triangle Park community. Our manufacturing footprint in the United States has played a critical role in Biogen’s history and success, and in advancing the treatments that are making an impact for patients, families, and communities here in the U.S. and around the world. With this investment, we will modernize and expand our manufacturing capability to enable our pipeline and provide resilient patient supply, while continuing to support the skilled and dedicated community of life sciences talent in North Carolina.”

Research Triangle Park remains Biogen’s largest global manufacturing site. The company is currently the largest biotechnology employer in North Carolina and ranks among the top five biopharmaceutical employers in the state. Biogen employs more than 1,500 manufacturing and technical professionals and over 400 skilled contractors at its campuses in Wake County and Durham County. 

More than 90% of the company’s commercial medicines are manufactured and undergo quality testing in the United States, with RTP playing a critical role in that process. This investment reinforces Biogen’s strategic commitment to North Carolina and to supporting global access to its medicines through advanced manufacturing capabilities.